BIOPHARMA

AbbVie's Humira (Adalimumab): A Biosimilar Is Easier Said Than Done

Tue Feb 23, 2016

Shares of AbbVie (NYSE:ABBV) are on the rebound after a sell-off in early February on concerns about the pending decision by an advisory panel to the Food and Drug ...

Biotechnology ETF (IBB) Trend Reversal, Is The Bottom In?

Wed Feb 10, 2016

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks the Nasdaq Biotechnology Index (NASDAQ:NBI), has been in free fall since the beginning of the year ...

Nasdaq Biotechnology Index Continues to Take a Beating as Campaign Rhetoric Becomes Increasing Louder ó What Do the Charts Say?

Mon Feb 1, 2016

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks the Nasdaq Biotechnology Index (NASDAQ: ...

Donald Trumpís Campaign Rhetoric Adds Volatility to the Nasdaq Biotechnology Index as U.S. Drug Companies Head to the Exits

Tue Jan 26, 2016

The iShares Nasdaq Biotechnology ETF [NASDAQ:IBB], which tracks the Nasdaq Biotechnology Index [NASDAQ: ...

Shares of Celgene Surge after USPTO Denies Institution of Kyle Bassís IPR Revlimid (lenalidomide) Patent Challenge

Mon Nov 16, 2015

Shares of Celgene Corp. [NASDAQ:CELG] soared 2.47% to close at $110.14 a share on Monday, after the U.S. Patent ...

Sarilumab, Sanofi and Regeneron's Next Potential Blockbuster Drug

Tue Nov 10, 2015

Sanofi [NYSE: SNY] and Regeneron Pharmaceuticals [NASDAQ:REGN] said on Sunday that their results from a pivotal Phase 3 study, SARIL-RA-TARGET, of sarilumab ...

Imbruvica (ibrutinib), the Next AbbVie Mega-Blockbuster Cancer Drug

Thu Nov 5, 2015

Shares of AbbVie [NYSE:ABBV] have surged 38.13% from the low of $45.45 a share on October 22, to close on Thursday at $62.78 a share. The company reported its third-quarter ...

Shire Shares Jump After Announcing Positive Topline Results from OPUS-3 Phase 3 Trial for its Dry Eye Disease Drug Lifitegrast

Tue Oct 27, 2015

Shares of Shire plc-ADR [NASDAQ:SHPG] jumped 7.73% to close at $227.71 a share on Tuesday, after the company ...

Biogen Beats Third-Quarter 2015 Earnings Estimates, Driven by Multiple Sclerosis Drug Tecfidera

Wed Oct 21, 2015

Biogen [NASDAQ:BIIB] shares surged 3.96% on Wednesday to close at $276.34 per share after the company reported ...

Presidential Candidates Trashing Biotech Companies Adds Volatility to the Nasdaq Biotechnology Index

Wed Oct 14, 2015

The iShares Nasdaq Biotechnology ETF [NASDAQ:IBB], which tracks the Nasdaq Biotechnology Index [NASDAQ ...

Novo Nordisk Shares Jump After FDA Approval for Tresiba and Ryzodeg for Patients with Type 1 and Type 2 Diabetes

Mon Sep 28, 2015

Shares of Novo Nordisk A/S (ADR) [NYSE:NVO] jumped 3.64% to an intraday high of $56.93 a share on Monday ...

Alnylam Pharmaceuticals Shares Tumbled After Presenting Initial Phase I Data of RNAi Therapeutic Targeting PCSK9, ALN-PCSsc

Tue Sep 1, 2015

Shares of Alnylam Pharmaceuticals [NASDAQ:ALNY] tumbled 5.65% to close at $102.91 a share on Monday ...

Jazz Pharmaceuticals Reported Strong Sales of Narcolepsy Drug Xyrem (sodium oxybate) but Foreign Currency Loss Weighs on Revenues

Wed Aug 19, 2015

In the second-quarter ended June 2015, Jazz Pharmaceuticals [NASDAQ:JAZZ] reported revenues of $333.75 million, up ...

Allergan Shares Rise as Sales Dramatically Increase in Dermatology and Aesthetics

Wed Aug 12, 2015

Wall Street is more bullish on Allergan PLC [NYSE:AGN] as the company is on a M&A shopping spree and is selling its slow growth and low margin business. Over the past two ...

Regeneron Shares Surged to Record High After Raising Eylea (aflibercept) Sales Forecast

Mon Aug 10, 2015

Shares of Regeneron Pharmaceuticals [NASDAQ:REGN] surged 9.32% to a record high of $605.93 per share on August 4 after the company announced a blowout earnings report ...

Shireís Defensive Acquisition Bid for Baxalta Dampens Speculations of the Company as a Takeover Target

Thu Aug 6, 2015

Shares of Shire PLC-ADR [NASDAQ:SHPG] fell 5.4% to close at $253.60 a share on Tuesday, after the company ...

Gilead Reports Strong Hepatitis C Drug Sales but may Need to Look Elsewhere for Growth

Fri Jul 31, 2015

Gilead Sciences [NASDAQ:GILD] just announced its blowout second-quarter ended June 2015 revenues of $8.24 billion, compared to $6.54 billion in 2014. Net income for the ...

AbbVie Shares Slipped on Concerns About Humira (adalimumab) Sales

Thu Jul 30, 2015

In the second quarter 2015, AbbVie [NYSE:ABBV] reported worldwide sales of $5.48 billion, up 11.1% year-over-year. On an operational basis, sales increased 19.4%, excluding ...

Biogen Shares Turn Binary After Releasing Mixed Interim Phase 1b Alzheimerís Drug BIIB037 Results and a Lowered Earnings Outlook

Tue Jul 28, 2015

Shares of Biogen [NASDAQ:BIIB] plunged 4.34% to close at $391.74 per share on July 22 after the company released ...

Celgene Shares Skyrocketed After Announcing Strong Preliminary Second Quarter Results and Acquisition of Immune-Inflammatory ...

Wed Jul 15, 2015

Shares of Celgene Corp. [NASDAQ:CELG] soared 10.69% to an intraday high of $135.98 share on Wednesday, after it ...

Most Recent Articles  |  Older Articles            

 Infotix Systems, Inc. - NMS (Not Main Street) Research - privacy & security policy
All rights reserved